Sector Update: Healthcare Shares Mixed Pre-Market; Sarepta Sinks 10% on GlaxoSmithKline, Prosensa Study


Shutterstock photo

Health care stocks:

JNJ: -0.01%

PFE: -0.14%

ABT: flat

MRK: -0.01%

AMGN: +0.22%

Healthcare shares are mixed in pre-market. Sarepta Therapeutics ( SRPT ) is down more than 10% after making sharp gains in pre-market trading, adding as much as 17% before slumping, after GlaxoSmithKline ( GSK ) and Prosensa ( RNA ) said their phase III clinical study for their Duchenne Muscular Dystrophy drug didn't meet the primary endpoint.

In the GSK and Prosensa study, the drisapersen drug didn't result in statistical significant improvement in the walking test. GSK is up 0.5% at $50.50.

And, in other healthcare news, GlaxoSmithKline and partner Theravance, Inc. ( THRX ) announced that the Japanese Ministry of Health, Labour and Welfare has approved RELVAR ELLIPTA for the treatment of bronchial asthma.

Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment of $10 million to GSK following, Japanese Ministry of Health approval of Relvar Ellipta. THRX is flat at $41.20.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , Commodities
More Headlines for: GSK , RNA , SRPT , THRX

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by